Researcher
Joery De Kock
- Keywords:Pharmacy and pharmacology
- Disciplines:Hepatology, Cell, tissue and organ engineering, In vitro testing, Hepatology (incl. pancreas), Biomarker discovery, Compound screening, Cellular therapy, Inflammation, Biopharmaceutics, Toxicogenomics, Gene and molecular therapy, Medical molecular engineering of nucleic acids and proteins
Affiliations
- Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2022 → Today - Pharmaceutical and Pharmacological Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From22 Jun 2017 → 7 Sep 2017 - Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2014 → 20 Oct 2022 - Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Jan 2014 → 30 Sep 2017 - Experimental in vitro toxicology and dermato-cosmetology (Research group)
Member
From21 Jun 2010 → 13 Jul 2024 - Toxicology, Dermato-cosmetology and Pharmacognosy (Department)
Member
From1 Oct 2006 → 31 Dec 2013
Projects
1 - 10 of 19
- 3D-CELLMAP: Unveiling complex cellular interactions in tissues through 3D super-resolution protein multiplex imagingFrom1 May 2024 → TodayFunding: FWO Medium Size Research Infrastructure
- EVOStAR: a strategic applicability and business plan roadmap for EVOZymes-based therapeutics.From1 Jan 2024 → TodayFunding: IOF - technology concept exploration
- BacTyriAL: Development of a new therapy for hereditary tyrosinemia type 1 using in vitro re-engineered bacterial tyrosine ammonia lyase enzymesFrom1 Nov 2023 → TodayFunding: FWO fellowships
- ExplorAKUre: Exploring genetically engineered tyrosine ammonia lyases as an mRNA-based therapy for alkaptonuriaFrom1 Nov 2023 → TodayFunding: FWO fellowships
- PiKachU: Development of human phenylalanine ammonia lyase (PAL) enzymes to treat phenylketonuria (PKU) using directed protein evolutionFrom1 Nov 2021 → TodayFunding: FWO fellowships
- TALENT: Engineering human tyrosine ammonia lyase (TAL) enzymes to treat inborn errors of tyrosine metabolismFrom1 Jan 2021 → TodayFunding: FWO research project (including WEAVE projects)
- H2020: CSA: TWINALT: Twinning towards excellence in alternative methods for toxicity assessmentFrom1 Sep 2020 → 31 Aug 2023Funding: H2020-EU.1.2.- EXCELLENT SCIENCE - Future and Emerging Technologies (FET)
- EvolvAKUre: a Darwinian approach to develop a cure for alkaptonuriaFrom1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- GEAR: Brussels Liver Research to Valorisation Alliance (B-Liver): Valorisation of VUB’s liver cell biology and toxicology expertise via a consortium focused on liver therapeutics, patient and consumer safety.From1 Jan 2020 → TodayFunding: IOF - technology concept exploration, IOF - mandates
- Non-Animal Methodologies for Toxicity Testing of Chemical Compounds (TOXIN).From1 Nov 2019 → TodayFunding: BOF - projects
Publications
1 - 10 of 77
- The Immunological Profile of Adipose Mesenchymal Stromal/Stem Cells after Cell Expansion and Inflammatory Priming(2024)
Authors: Karolien Buyl, Makram Merimi, Robim Rodrigues, Saida Rahmani, Mohammad Fayyad-Kazan, Fatima Bouhtit, Noureddine Boukhatem, Tamara Vanhaecke, Hassan Fahmi, Joery De Kock, et al.
- Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis(2023)
Authors: Karolien Buyl, Martine Vrints, Ruani Fernando, Terry Desmae, Thomas Van Eeckhoutte, Mia Jans, Jan Van Der Schueren, Joost Boeckmans, Robim Rodrigues, Veerle De Boe, et al.
- Short-term nitisinone discontinuation of hereditary tyrosinemia type 1 mice causes metabolic alterations in glutathione metabolism/biosynthesis and multiple amino acid degradation pathways(2023)
Authors: Haaike Colemonts-Vroninks, Brendan Norman, Sven Van Laere, Andrew Davison, Lionel Marcélis, G. Casimir, Philippe Goyens, Paul Claes, Dimitri De Bundel, Geert A Martens, et al.
Pages: 1759-1762 - Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype(2023)
Authors: Jessie Neuckermans, Sien Lequeue, Paul Claes, Anja Heymans, Juliette H Hughes, Haaike Colemonts-Vroninks, Lionel Marcélis, Georges Casimir, Philippe Goyens, Geert A Martens, et al.
- Functional characterisation of genes and metabolites involved in the metabolic and neurocognitive pathophysiology of hereditary tyrosinemia type 1(2023)
Authors: Haaike Colemonts-Vroninks, Joery De Kock, Tamara Vanhaecke, Dimitri De Bundel, Geert Martens
Number of pages: 184 - Light triggered nanoscale biolistics for efficient intracellular delivery of functional macromolecules in mammalian cells(2022)
Authors: Juan C Fraire, Elnaz Shaabani, Maryam Sharifiaghdam, Matthias Rombaut, Charlotte Hinnekens, Dawei Hua, Jana Ramon, Laurens Raes, Eduardo Bolea-Fernandez, Toon Brans, et al.
- A robust bacterial high-throughput screening system to evaluate single nucleotide polymorphisms of human homogentisate 1,2-dioxygenase in the context of alkaptonuria(2022)
Authors: Sien Lequeue, Jessie Neuckermans, Ine Nulmans, Ulrich Schwaneberg, Tamara Vanhaecke, Joery De Kock
Pages: 1-15 - The Current Status and Work of Three Rs Centres and Platforms in Europe(2022)
Authors: Winfried Neuhaus, Birgit Reininger-Gutmann, Beate Rinner, Roberto Plasenzotti, Doris Wilflingseder, Joery De Kock, Tamara Vanhaecke, Vera Rogiers, Dagmar Jírová, Kristina Kejlová, et al.
Pages: 381-413 - Development of an adverse outcome pathway network for breast cancer: a comprehensive representation of the pathogenesis, complexity and diversity of the disease(2022)
Authors: Gigly Del'Haye, Ine Nulmans, Sandrine Paula Bouteille, Karolien Sermon, Brecht Wellekens, Matthias Rombaut, Tamara Vanhaecke, Yvan Vander Heyden, Joery De Kock
Pages: 2881-2897 - End-user engineering of ontology-based knowledge bases(2022)
Authors: Audrey Sanctorum, Jonathan Riggio, Jan Maushagen, Sara Sepehri, Emma Gustafson, Mona Delagrange, Joery De Kock, Tamara Vanhaecke, Christophe Debruyne, Olga De Troyer
Pages: 1811-1829